CD8A and Decreased total leukocyte count: Because mild leukopenia is observed clinically in patients receiving venetoclax for malignancy (70), we assessed cellular dynamics of treated mice; hCD45- and hCD8-positive cells declined in the venetoclax-treated group compared to control (Fig. 6A and B), yet CD4:CD8 ratios normalized to >1 at week 6 in the venetoclax-treated group (P = 0.0281) (Fig. 6D), and we observed an increased percentage of hCD4 cells at weeks 8 and 10 (P = 0.045 and 0.005) (Fig. 6E).